Mylan submits ANDA for generic Advair Diskus

PITTSBURGH — Mylan on Tuesday announced that it had submitted to the Food and Drug Administration an abbreviated new drug application (ANDA) for Advair Diskus (fluticasone propionate and salmeterol inhalation powder). 

 

The drug is intended to treat asthma and the maintenance of airflow obstruction and reducing exacerbations among patients with chronic obstructive pulmonary disease. Mylan said it would provide updates as the approval process continues.